The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...
The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...
Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...
In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...
What if we would have watched it for six months? Like, I possibly couldn’t be here talking to you and have lived my life six ...
On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback